These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 7588568)

  • 21. SAMP14, a novel, acrosomal membrane-associated, glycosylphosphatidylinositol-anchored member of the Ly-6/urokinase-type plasminogen activator receptor superfamily with a role in sperm-egg interaction.
    Shetty J; Wolkowicz MJ; Digilio LC; Klotz KL; Jayes FL; Diekman AB; Westbrook VA; Farris EM; Hao Z; Coonrod SA; Flickinger CJ; Herr JC
    J Biol Chem; 2003 Aug; 278(33):30506-15. PubMed ID: 12788941
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
    Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
    Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis.
    Roldan AL; Cubellis MV; Masucci MT; Behrendt N; Lund LR; Danø K; Appella E; Blasi F
    EMBO J; 1990 Feb; 9(2):467-74. PubMed ID: 1689240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity.
    Czekay RP; Kuemmel TA; Orlando RA; Farquhar MG
    Mol Biol Cell; 2001 May; 12(5):1467-79. PubMed ID: 11359936
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.
    Solberg H; Rømer J; Brünner N; Holm A; Sidenius N; Danø K; Høyer-Hansen G
    Int J Cancer; 1994 Sep; 58(6):877-81. PubMed ID: 7927882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies.
    Rønne E; Høyer-Hansen G; Brünner N; Pedersen H; Rank F; Osborne CK; Clark GM; Danø K; Grøndahl-Hansen J
    Breast Cancer Res Treat; 1995 Mar; 33(3):199-207. PubMed ID: 7749147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
    Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
    Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling.
    Solberg H; Ploug M; Høyer-Hansen G; Nielsen BS; Lund LR
    J Histochem Cytochem; 2001 Feb; 49(2):237-46. PubMed ID: 11156692
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae.
    Stahl A; Mueller BM
    J Cell Biol; 1995 Apr; 129(2):335-44. PubMed ID: 7721938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria.
    Rønne E; Pappot H; Grøndahl-Hansen J; Høyer-Hansen G; Plesner T; Hansen NE; Danø K
    Br J Haematol; 1995 Mar; 89(3):576-81. PubMed ID: 7734357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.
    Busso N; Masur SK; Lazega D; Waxman S; Ossowski L
    J Cell Biol; 1994 Jul; 126(1):259-70. PubMed ID: 7517943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain.
    Høyer-Hansen G; Rønne E; Solberg H; Behrendt N; Ploug M; Lund LR; Ellis V; Danø K
    J Biol Chem; 1992 Sep; 267(25):18224-9. PubMed ID: 1381366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. cDNA for Mo3, a monocyte activation antigen, encodes the human receptor for urokinase plasminogen activator.
    Min HY; Semnani R; Mizukami IF; Watt K; Todd RF; Liu DY
    J Immunol; 1992 Jun; 148(11):3636-42. PubMed ID: 1316922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of purified, soluble urokinase receptor on the plasminogen-prourokinase activation system.
    Behrendt N; Danø K
    FEBS Lett; 1996 Sep; 393(1):31-6. PubMed ID: 8804418
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.
    Vines DJ; Lee SW; Dichek DA; Ellis V
    J Pept Sci; 2000 Sep; 6(9):432-9. PubMed ID: 11016879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
    Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
    Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.